• en
  • sv

ADDvise receives allocation decision worth approximately MSEK 8 – Regulatory information

31 Aug, 2020

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from Jyväskylä Hospital NEO in Finland worth approximately MSEK 8. The allocation decision consists of orders during three years regarding ultrasound systems for use in healthcare.  

In accordance with Finnish procurement law can the allocation decision be appealed directly to the procuring unit, which two participants have decided to do.
 

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

 

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 31 August 2020 at 17:10 CEST.
 

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Ladda ned pressmeddelande